187 related articles for article (PubMed ID: 28287509)
1. Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.
MacLachlan BJ; Greenshields-Watson A; Mason GH; Schauenburg AJ; Bianchi V; Rizkallah PJ; Sewell AK; Fuller A; Cole DK
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287509
[TBL] [Abstract][Full Text] [Related]
2. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
[TBL] [Abstract][Full Text] [Related]
4. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
Bianchi V; Bulek A; Fuller A; Lloyd A; Attaf M; Rizkallah PJ; Dolton G; Sewell AK; Cole DK
J Biol Chem; 2016 Apr; 291(17):8951-9. PubMed ID: 26917722
[TBL] [Abstract][Full Text] [Related]
5. Highly divergent T-cell receptor binding modes underlie specific recognition of a bulged viral peptide bound to a human leukocyte antigen class I molecule.
Liu YC; Miles JJ; Neller MA; Gostick E; Price DA; Purcell AW; McCluskey J; Burrows SR; Rossjohn J; Gras S
J Biol Chem; 2013 May; 288(22):15442-54. PubMed ID: 23569211
[TBL] [Abstract][Full Text] [Related]
6. Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.
Hiscox MJ; Wasmuth A; Williams CL; Foot JN; Wiedermann GE; Fadda V; Boiani S; Cornforth TV; Wikiert KA; Bruton S; Cartwright N; Anderson VE; Barnes CS; Vieira JV; Birch-Machin I; Gerry AB; Miller K; Pumphrey NJ
PLoS One; 2024; 19(4):e0301175. PubMed ID: 38574067
[TBL] [Abstract][Full Text] [Related]
7. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.
Gee MH; Han A; Lofgren SM; Beausang JF; Mendoza JL; Birnbaum ME; Bethune MT; Fischer S; Yang X; Gomez-Eerland R; Bingham DB; Sibener LV; Fernandes RA; Velasco A; Baltimore D; Schumacher TN; Khatri P; Quake SR; Davis MM; Garcia KC
Cell; 2018 Jan; 172(3):549-563.e16. PubMed ID: 29275860
[TBL] [Abstract][Full Text] [Related]
8. Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition.
Szeto C; Bloom JI; Sloane H; Lobos CA; Fodor J; Jayasinghe D; Chatzileontiadou DSM; Grant EJ; Buckle AM; Gras S
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992915
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
10. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
11. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
12. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
[TBL] [Abstract][Full Text] [Related]
13. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
14. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
15. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
16. Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
Hansen BE; Rasmussen AH; Jakobsen BK; Ryder LP; Svejgaard A
Tissue Antigens; 2007 Jul; 70(1):42-52. PubMed ID: 17559580
[TBL] [Abstract][Full Text] [Related]
17. Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy.
Crean RM; MacLachlan BJ; Madura F; Whalley T; Rizkallah PJ; Holland CJ; McMurran C; Harper S; Godkin A; Sewell AK; Pudney CR; van der Kamp MW; Cole DK
Mol Ther Oncolytics; 2020 Sep; 18():443-456. PubMed ID: 32913893
[TBL] [Abstract][Full Text] [Related]
18. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
19. Engineering soluble T-cell receptors for therapy.
Robinson RA; McMurran C; McCully ML; Cole DK
FEBS J; 2021 Nov; 288(21):6159-6173. PubMed ID: 33624424
[TBL] [Abstract][Full Text] [Related]
20. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.
Obenaus M; Leitão C; Leisegang M; Chen X; Gavvovidis I; van der Bruggen P; Uckert W; Schendel DJ; Blankenstein T
Nat Biotechnol; 2015 Apr; 33(4):402-7. PubMed ID: 25774714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
